Integral Health Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Integral Health Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$65.7M	Sell	85,000 -20,000	-19%	-$15.3M	3.14%	6
2025 Q4	$81M	Buy	105,000 +55,000	+110%	+$37.4M	4.02%	5
2025 Q3	$28.1M	Hold	50,000	–	–	1.9%	11
2025 Q2	$26.3M	Buy	+50,000	New	+$27.9M	2.4%	10
2024 Q2	–	Sell	-17,000	Closed	-$16.4M	–	97
2024 Q1	$16.4M	Sell	17,000 -8,000	-32%	-$7.61M	1.52%	23
2023 Q4	$22M	Buy	+25,000	New	+$20.6M	2.99%	6
2023 Q2	–	Sell	-3,000	Closed	-$2.47M	–	96
2023 Q1	$2.47M	Buy	+3,000	New	+$2.26M	0.5%	57
2021 Q4	–	Sell	-10,000	Closed	-$6.05M	–	82
2021 Q3	$6.05M	Sell	10,000 -8,500	-46%	-$5.28M	1.74%	20
2021 Q2	$10.3M	Buy	+18,500	New	+$9.37M	2.84%	7
2020 Q3	–	Sell	-12,000	Closed	-$7.48M	–	85
2020 Q2	$7.48M	Buy	+12,000	New	+$6.81M	2.24%	18

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Integral Health Asset Management's REGN Position: Q1 2026 in Review

Integral Health Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 19% in Q1 2026, selling an estimated $15.3M and leaving 85,000 shares worth $65.7M. The position accounts for 3.14% of the portfolio, ranked #6.

Integral Health Asset Management first reported a position in REGN in Q2 2020 and has held it in 10 quarters since. The position peaked at $81M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Integral Health Asset Management held 85,000 shares of Regeneron Pharmaceuticals worth $65.7M as of Q1 2026.
Integral Health Asset Management sold 20,000 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $15.3M.
Regeneron Pharmaceuticals made up 3.14% of Integral Health Asset Management's portfolio in Q1 2026, its #6 holding.
Integral Health Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 10 quarters since.
Integral Health Asset Management's Regeneron Pharmaceuticals position peaked at $81M in Q4 2025.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.